Otherwise, practitioners also can use IHC, FISH, and polymerase chain reaction (PCR) to target specific gene alterations, such as MET with high GCN or HER-2 with IHC3 + , and identify corresponding patients such as patients with locally advanced and advanced lung cancer who may benefit from targeted therapies. This evidence concerns the gene MET and lung cancer.